

This requisition form can be used to submit an order for the **Invitae Detect Cardiomyopathy and Arrhythmia program**, a sponsored testing program for familial cardiomyopathies or arrhythmias.

**INSTRUCTIONS:** Review the ordering options and then complete all sections of this form. Your ordering option will be indicated in the test selection section.

### ORDERING OPTIONS

#### 1. DETECT CARDIOMYOPATHY AND ARRHYTHMIA PROGRAM

For individuals that meet the eligibility criteria below and wish to receive the program specific genetic testing panels.

**REQUIRED:** You must select below the appropriate eligibility criteria for this patient.

**This program is available to patients in the U.S. and Canada suspected of having a familial cardiomyopathy or arrhythmia (select one or more):**

- |  |  |
|--|--|
| <input type="radio"/> Suspicion or known diagnosis of a familial cardiomyopathy or arrhythmia<br>Diagnosis: <input type="radio"/> HCM <input type="radio"/> DCM <input type="radio"/> ARVC <input type="radio"/> LVNC<br><input type="radio"/> LQTS <input type="radio"/> CPVT <input type="radio"/> BrS <input type="radio"/> Other: _____<br>Age at diagnosis: _____<br>Index of clinical suspicion: <input type="radio"/> High <input type="radio"/> Moderate <input type="radio"/> Low | <input type="radio"/> Family history of unexplained sudden cardiac death<br>Age(s): _____<br><input type="radio"/> Patient is deceased* <input type="radio"/> Yes <input type="radio"/> No<br>*If the patient is deceased please also complete the postmortem consent form located at <a href="http://www.invitae.com/postmortem-consent">www.invitae.com/postmortem-consent</a> |
| <input type="radio"/> Family history of a primary cardiomyopathy or arrhythmia<br>Diagnosis: <input type="radio"/> HCM <input type="radio"/> DCM <input type="radio"/> ARVC <input type="radio"/> LVNC<br><input type="radio"/> LQTS <input type="radio"/> CPVT <input type="radio"/> BrS <input type="radio"/> Other: _____   |  |

#### 2. GENE-SPECIFIC FAMILY FOLLOW-UP TESTING

For relatives of program participants who received a Pathogenic/Likely Pathogenic result or approved VUS who want to receive gene specific family follow-up testing at no additional cost. Relatives do not need to meet the eligibility criteria listed above. Learn more at [www.invitae.com/family](http://www.invitae.com/family).

#### PATIENT INFORMATION

First name	MI	Last name
Date of birth (MM/DD/YYYY)	Biological sex <input type="radio"/> M <input type="radio"/> F	MRN (medical record number)
Ancestry <input type="radio"/> Asian <input type="radio"/> Black/African American <input type="radio"/> White/Caucasian <input type="radio"/> Ashkenazi Jewish <input type="radio"/> Hispanic <input type="radio"/> Native American <input type="radio"/> Pacific Islander <input type="radio"/> French Canadian <input type="radio"/> Sephardic Jewish <input type="radio"/> Mediterranean <input type="radio"/> Other: _____		
Phone	Email address (report access after clinician releases)	
Address		City
State/Prov	ZIP/Postal code	Country
Ship a saliva kit to this patient (to submit, fax this form to Client Services at 415-276-4164) <input type="radio"/> Ship kit to address above <input type="radio"/> Ship kit to alternate address: _____		

#### SPECIMEN INFORMATION

**Specimen type:** Blood (3-mL purple EDTA) **-OR-** Saliva (Oragene™) **-OR-** Assisted Saliva **-OR-** DNA source: \_\_\_\_\_

*We are unable to accept blood/saliva from patients with:*  
 • Allogeneic bone marrow transplants • Blood transfusion <2 weeks prior to specimen collection

**Specimen collection date (MM/DD/YYYY):**     
*If not provided, the day before specimen receipt will be used*

**Special cases:**  History of/current hematologic malignancy in patient

#### CLINICIAN INFORMATION

Organization name		
Phone	Fax	
Address		City
State/Prov	ZIP/Postal code	Country
<b>Primary clinical contact name</b> (if different from ordering provider)		NPI
Primary clinical contact email address (for report access)		
<b>Ordering provider (select one ordering provider by marking the checkbox before the name)</b>		
<input type="radio"/>	Name	NPI
<input type="radio"/>	Email address (for report access)	
<input type="radio"/>	_____	
<b>Additional clinical or laboratory contacts (optional, to share access to order online)</b>		
<input type="radio"/> Share this order with the primary clinical contact's default clinical team, manage at <a href="http://www.invitae.com">www.invitae.com</a>		
<input type="radio"/>	Name	Email address (for report access)
<input type="radio"/>	Name	Email address (for report access)

**INVITAE PARTNER CODE**
**CARDIO**



**TEST SELECTION – Select option 1 or 2 below:**
 **1. DETECT CARDIOMYOPATHY AND ARRHYTHMIA PROGRAM – Indicate test(s) to be performed below:**

Test code	Test name	# of genes	Gene list
<input checked="" type="radio"/> 02101	Invitae Arrhythmia and Cardiomyopathy Comprehensive Panel	67	ABCC9, ACTC1, ACTN2, AGL, ANK2, BAG3, CACNA1C, CACNB2, CALM1, CALM2, CALM3, CASQ2, CAV3, CRYAB, CSRP3, DES, DMD, DOLK, DSC2, DSG2, DSP, EMD, EYA4, FHL1, FKRP, FKTN, FLNC, GAA, GLA, GPD1L, HCN4, JUP, KCNA5, KCNE1, KCNE2, KCNH2, KCNJ2, KCNQ1, LAMP2, LMNA, MYBPC3, MYH7, MYL2, MYL3, MYL4, NKX2-5, PKP2, PLN, PRKAG2, RAF1, RBM20, RYR2, SCN5A, SGC2, SLC22A5, TAZ, TCAP, TGFB3, TMEM43, TNNC1, TNNI3, TNNT2, TPM1, TRDN, TTN, TTR, VCL
<input type="radio"/> 02101.1	Add-on preliminary-evidence genes	47	AKAP9, ANKRD1, CACNA2D1, CALR3, CHRM2, CTF1, CTNNA3, DTNA, FHL2, GATA4, GATA6, GATAD1, GJA5, ILK, JPH2, KCND3, KCNE3, KCNE5, KCNJ5, KCNJ8, KCNK3, LAMA4, LDB3, LRRC10, MED12, MYH6, MYLK2, MYOM1, MYOZ2, MYPN, NEBL, NEXN, NPPA, PDLIM3, PLEKHM2, PRDM16, RANGRF, SCN10A, SCN1B, SCN2B, SCN3B, SCN4B, SLMAP, SNTA1, TMPO, TRPM4, TXNRD2
<input type="radio"/> 02101.2	Add-on RASopathy genes not included in panel	17	A2ML1, BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NF1, NRAS, PTPN11, RASA1, RIT1, RRAS, SHOC2, SOS1, SOS2, SPRED1
<input type="radio"/> 02101.3	Add-on genes associated with autosomal recessive syndromic pediatric cardiomyopathy	8	ACADVL, ALMS1, CPT2, DNAJC19, ELAC2, MTO1, SDHA, TMEM70
<input type="radio"/> 02101.4	Add-on sudden unexpected death in epilepsy (SUDEP) genes for arrhythmia and cardiomyopathy	11	DEPDC5, KCNA1, KCNQ2, KCNQ3, KCNT1, PCDH19, PRRT2, SCN1A, SCN8A, SCN9A, SLC2A1

 **2. GENE-SPECIFIC FAMILY FOLLOW-UP TESTING** *For relatives of a program participant ("proband") who received a Pathogenic/Likely Pathogenic result or approved VUS.*

<b>Proband's Invitae Order ID:</b> RQ# _____	<b>This patient's relationship to proband:</b> <input type="radio"/> Parent <input type="radio"/> Sibling <input type="radio"/> Grandchild <input type="radio"/> Child <input type="radio"/> Other: _____	<b>Gene(s) to be tested in this patient:</b>
---	---	--

**NOTE:** The presence or absence of all variants identified in the proband for the gene(s) ordered for gene-specific family follow-up will be commented on in this patient's report unless a limited selection is specified in the **Requested Variants** section above. Invitae will report any Pathogenic/Likely Pathogenic variants found in this patient for the gene(s) ordered.

Invitae continually updates its panels based on the most recent evidence. If an order is placed using an outdated test requisition form, Invitae reserves the right to upgrade ordered tests to their current versions. Test IDs containing add-on codes will include the original panel as well as the add-on.

By signing this form, the medical professional acknowledges that the individual/family member authorized to make decisions for the individual (collectively, the "Patient") has been supplied information regarding and consented to undergo genetic testing, substantially as set forth in Invitae's Informed Consent for Genetic Testing ([www.invitae.com/forms](http://www.invitae.com/forms)). In connection with the Program the Patient has been informed that Invitae may notify them of clinical updates related to genetic test results (in consultation with the ordering medical professional as indicated) and has been informed that de-identified Patient data may be used and shared with third parties, for research and commercial purposes and, in the U.S., to contact their medical professional. For orders originating in Canada, the Patient has been informed that their personal information and specimen will be transferred to and processed in the U.S. and that de-identified Patient data may be used and shared for research and commercial purposes in the U.S. The medical professional warrants that he/she will not seek reimbursement for this nocharge test from any third party, including but not limited to federal healthcare programs. The medical professional also hereby acknowledges that organization and clinician contact information provided in the order may be shared with third parties, including commercial organizations, that may contact the medical professional directly in connection with the Program, and that they have made the Patient aware that de-identified Patient data may be used and shared with such third parties, for purposes which include contacting their medical professional directly in connection with the Program. A list of third party partners may be provided upon request. I attest that I am authorized under applicable state law to order this test.

**Medical professional signature (required)**
**Date (MM/DD/YYYY)**